

# Yi Lin

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3140714/publications.pdf>

Version: 2024-02-01

233  
papers

17,205  
citations

46918

47  
h-index

16127

124  
g-index

235  
all docs

235  
docs citations

235  
times ranked

14040  
citing authors

#	ARTICLE	IF	CITATIONS
1	Ciltacabtagene Autoleucl, an Anti-CD19 B-cell Maturation Antigen Chimeric Antigen Receptor T-Cell Therapy, for Relapsed/Refractory Multiple Myeloma: CARTITUDE-1 2-Year Follow-Up. <i>Journal of Clinical Oncology</i> , 2023, 41, 1265-1274.	0.8	160
2	Critically Ill Patients Treated for Chimeric Antigen Receptor-Related Toxicity: A Multicenter Study*. <i>Critical Care Medicine</i> , 2022, 50, 81-92.	0.4	13
3	Mortality trends in multiple myeloma after the introduction of novel therapies in the United States. <i>Leukemia</i> , 2022, 36, 801-808.	3.3	43
4	Comparison of Cilta-cel, an Anti-BCMA CAR-T Cell Therapy, Versus Conventional Treatment in Patients With Relapsed/Refractory Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2022, 22, 326-335.	0.2	27
5	Characteristics and risk factors for thrombosis in POEMS syndrome: A retrospective evaluation of 230 patients. <i>American Journal of Hematology</i> , 2022, 97, 209-215.	2.0	5
6	Impact of achieving a complete response to initial therapy of multiple myeloma and predictors of subsequent outcome. <i>American Journal of Hematology</i> , 2022, , .	2.0	5
7	Does bridging radiation therapy affect the pattern of failure after CAR T-cell therapy in non-Hodgkin lymphoma?. <i>Radiotherapy and Oncology</i> , 2022, 166, 171-179.	0.3	27
8	A simple additive staging system for newly diagnosed multiple myeloma. <i>Blood Cancer Journal</i> , 2022, 12, 21.	2.8	30
9	Multicentric Castleman disease: A single center experience of treatment with a focus on autologous stem cell transplantation. <i>American Journal of Hematology</i> , 2022, , .	2.0	2
10	Next generation sequencing (NGS) to identify relapsed gastrointestinal (GI) solid tumor patients with human leukocyte antigen (HLA) loss of heterozygosity (LOH) for future logic-gated CAR T therapy to reduce on target off tumor toxicity.. <i>Journal of Clinical Oncology</i> , 2022, 40, 190-190.	0.8	2
11	Incidence of thrombosis in relapsed/refractory B-cell lymphoma treated with axicabtagene ciloleucl: Mayo Clinic experience. <i>Leukemia and Lymphoma</i> , 2022, 63, 1363-1368.	0.6	4
12	Utility of PET/CT in assessing early treatment response in patients with newly diagnosed multiple myeloma. <i>Blood Advances</i> , 2022, 6, 2763-2772.	2.5	13
13	Cardiotoxicity from chimeric antigen receptor-T cell therapy for advanced malignancies. <i>European Heart Journal</i> , 2022, 43, 1928-1940.	1.0	39
14	Peak absolute lymphocyte count after CAR-T infusion predicts clinical response in aggressive lymphoma. <i>American Journal of Hematology</i> , 2022, 97, .	2.0	2
15	Allogeneic Chimeric Antigen Receptor Therapy in Lymphoma. <i>Current Treatment Options in Oncology</i> , 2022, 23, 171-187.	1.3	9
16	Metabolic characteristics and prognostic differentiation of aggressive lymphoma using one-month post-CAR-T FDG PET/CT. <i>Journal of Hematology and Oncology</i> , 2022, 15, 36.	6.9	17
17	Acute seizures and status epilepticus in immune effector cell associated neurotoxicity syndrome (ICANS). <i>Blood Cancer Journal</i> , 2022, 12, 62.	2.8	6
18	Longitudinal Patient Reported Outcomes with CAR-T Cell Therapy Versus Autologous and Allogeneic Stem Cell Transplant. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 473-482.	0.6	20

#	ARTICLE	IF	CITATIONS
19	Patient Experience in Clinical Trials: Quality of Life, Financial Burden, and Perception of Care in Patients With Multiple Myeloma or Lymphoma Enrolled on Clinical Trials Compared With Standard Care. <i>JCO Oncology Practice</i> , 2022, , OP2100789.	1.4	0
20	Meta-analysis of ciltacabtagene autoleucl versus physician's choice therapy for the treatment of patients with relapsed or refractory multiple myeloma. <i>Current Medical Research and Opinion</i> , 2022, 38, 1759-1767.	0.9	5
21	Outcomes of Patients with Large B-cell Lymphoma Progressing after Axicabtagene Ciloleucl. <i>Blood</i> , 2021, 137, 1832-1835.	0.6	48
22	Implications of detecting serum monoclonal protein by MASS-Fix following stem cell transplantation in multiple myeloma. <i>British Journal of Haematology</i> , 2021, 193, 380-385.	1.2	21
23	Idecabtagene Vicleucl in Relapsed and Refractory Multiple Myeloma. <i>New England Journal of Medicine</i> , 2021, 384, 705-716.	13.9	1,129
24	Clinical Characteristics and Outcomes of Patients With Primary Plasma Cell Leukemia in the Era of Novel Agent Therapy. <i>Mayo Clinic Proceedings</i> , 2021, 96, 677-687.	1.4	16
25	MASS-FIX for the detection of monoclonal proteins and light chain N-glycosylation in routine clinical practice: a cross-sectional study of 6315 patients. <i>Blood Cancer Journal</i> , 2021, 11, 50.	2.8	25
26	Impact of hypoalbuminemia on the prognosis of relapsed/refractory B-cell lymphoma treated with axicabtagene ciloleucl. <i>European Journal of Haematology</i> , 2021, 107, 48-53.	1.1	3
27	KTE-X19 anti-CD19 CAR T-cell therapy in adult relapsed/refractory acute lymphoblastic leukemia: ZUMA-3 phase 1 results. <i>Blood</i> , 2021, 138, 11-22.	0.6	90
28	Prognostic role of lymphocyte to monocyte ratio in patients treated with CAR-T for aggressive lymphoma.. <i>Journal of Clinical Oncology</i> , 2021, 39, 7558-7558.	0.8	0
29	Outcomes in primary cutaneous diffuse large B-cell lymphoma, leg type.. <i>Journal of Clinical Oncology</i> , 2021, 39, e19547-e19547.	0.8	2
30	Survival trends of older adult patients with diffuse large B-cell lymphoma: A National Cancer Database analysis.. <i>Journal of Clinical Oncology</i> , 2021, 39, 7542-7542.	0.8	1
31	Outpatient practice pattern and remote patient monitoring for axicabtagene ciloleucl CAR-T therapy in patients with aggressive lymphoma.. <i>Journal of Clinical Oncology</i> , 2021, 39, 7554-7554.	0.8	7
32	Characteristics, outcomes, and risk factors of ICANS after axicabtagene ciloleucl: Does age matter?. <i>Journal of Clinical Oncology</i> , 2021, 39, e19556-e19556.	0.8	2
33	Vaccine titers in lymphoma patients receiving chimeric antigen receptor T-cell therapy.. <i>Journal of Clinical Oncology</i> , 2021, 39, 7555-7555.	0.8	1
34	Impact of stratifying levels of serum lactate dehydrogenase (LDH) at diagnosis on the overall survival (OS) in newly diagnosed multiple myeloma (NDMM).. <i>Journal of Clinical Oncology</i> , 2021, 39, e20016-e20016.	0.8	0
35	Phase 2 results of the ZUMA-3 study evaluating KTE-X19, an anti-CD19 chimeric antigen receptor (CAR) T-cell therapy, in adult patients (pts) with relapsed/refractory B-cell acute lymphoblastic leukemia (R/R) Tj ETQq1 1 0.784314 7gBT /Over	0.8	1
36	Real-world evidence of axicabtagene ciloleucl (Axi-cel) for the treatment of large B-cell lymphoma (LBCL) in the United States (US).. <i>Journal of Clinical Oncology</i> , 2021, 39, 7552-7552.	0.8	5

#	ARTICLE	IF	CITATIONS
37	Systematic Review of Risk factors and Incidence of Acute Kidney Injury Among Patients Treated with CAR-T Cell Therapies. <i>Kidney International Reports</i> , 2021, 6, 1416-1422.	0.4	17
38	Outcomes in mantle cell lymphoma with central nervous system involvement.. <i>Journal of Clinical Oncology</i> , 2021, 39, e19527-e19527.	0.8	4
39	Characteristics of neurotoxicity associated with idecabtagene vicleucel (ide-cel, bb2121) in patients with relapsed and refractory multiple myeloma (RRMM) in the pivotal phase II KarMMA study.. <i>Journal of Clinical Oncology</i> , 2021, 39, 8036-8036.	0.8	3
40	The impact of body weight and body mass index on outcomes of diffuse large B-cell lymphoma treated with axicabtagene ciloleucel.. <i>Journal of Clinical Oncology</i> , 2021, 39, e19554-e19554.	0.8	0
41	Treatment of AL Amyloidosis: Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Statement 2020 Update. <i>Mayo Clinic Proceedings</i> , 2021, 96, 1546-1577.	1.4	32
42	The Impact of Socioeconomic Risk Factors on the Survival Outcomes of Patients With Newly Diagnosed Multiple Myeloma: A Cross-analysis of a Population-based Registry and a Tertiary Care Center. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, 451-460.e2.	0.2	9
43	Lines of therapy before autologous stem cell transplant and <sc>CAR</sc> affect outcomes in aggressive <sc>Non-Hodgkin's</sc> lymphoma. <i>American Journal of Hematology</i> , 2021, 96, E386-E389.	2.0	4
44	The impact of obesity and body weight on the outcome of patients with relapsed/refractory large B-cell lymphoma treated with axicabtagene ciloleucel. <i>Blood Cancer Journal</i> , 2021, 11, 124.	2.8	9
45	Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study. <i>Lancet, The</i> , 2021, 398, 314-324.	6.3	711
46	The impact of granulocyte colony stimulating factor on patients receiving chimeric antigen receptor <sc>T</sc> cell therapy. <i>American Journal of Hematology</i> , 2021, 96, E399-E402.	2.0	14
47	Outcomes in primary cutaneous diffuse large B cell lymphoma, leg type. <i>Hematological Oncology</i> , 2021, 39, 658-663.	0.8	8
48	Age defining immune effector cell associated neurotoxicity syndromes in aggressive large <sc>B</sc> cell lymphoma patients treated with axicabtagene ciloleucel. <i>American Journal of Hematology</i> , 2021, 96, E427-E430.	2.0	7
49	Comparison of the current renal staging, progression and response criteria to predict renal survival in <sc>AL</sc> amyloidosis using a <sc>Mayo</sc> cohort. <i>American Journal of Hematology</i> , 2021, 96, 446-454.	2.0	8
50	Prognostic significance of acquired 1q22 gain in multiple myeloma. <i>American Journal of Hematology</i> , 2021, , .	2.0	6
51	Brexucabtagene Autoleucel for Relapsed/Refractory Mantle Cell Lymphoma: Real World Experience from the US Lymphoma CAR T Consortium. <i>Blood</i> , 2021, 138, 744-744.	0.6	15
52	Barriers to Enrollment in Clinical Trials in Patients with Aggressive B-Cell Non-Hodgkin Lymphoma That Progressed after Anti-CD19 CART Cell Therapy. <i>Blood</i> , 2021, 138, 2527-2527.	0.6	3
53	Survival impact of achieving minimal residual negativity by multi-parametric flow cytometry in AL amyloidosis. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2020, 27, 13-16.	1.4	25
54	Cytogenetic Features and Clinical Outcomes of Patients With Non-secretory Multiple Myeloma in the Era of Novel Agent Induction Therapy. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, 53-56.	0.2	8

#	ARTICLE	IF	CITATIONS
55	Enhancing the Râ€SS classification of newly diagnosed multiple myeloma by quantifying circulating clonal plasma cells. <i>American Journal of Hematology</i> , 2020, 95, 310-315.	2.0	37
56	Light chain amyloidosis induced inflammatory changes in cardiomyocytes and adipose-derived mesenchymal stromal cells. <i>Leukemia</i> , 2020, 34, 1383-1393.	3.3	17
57	Implications and outcomes of MRDâ€negative multiple myeloma patients with immunofixation positivity. <i>American Journal of Hematology</i> , 2020, 95, E60-E62.	2.0	4
58	Impact of MYD88<sup>L265P</sup> mutation status on histological transformation of WaldenstrÃ¶m Macroglobulinemia. <i>American Journal of Hematology</i> , 2020, 95, 274-281.	2.0	33
59	Bone marrow plasma cells 20% or greater discriminate presentation, response, and survival in AL amyloidosis. <i>Leukemia</i> , 2020, 34, 1135-1143.	3.3	29
60	Th17-inducing autologous dendritic cell vaccination promotes antigen-specific cellular and humoral immunity in ovarian cancer patients. <i>Nature Communications</i> , 2020, 11, 5173.	5.8	46
61	Implications of MYC Rearrangements in Newly Diagnosed Multiple Myeloma. <i>Clinical Cancer Research</i> , 2020, 26, 6581-6588.	3.2	32
62	Tumor burden, inflammation, and product attributes determine outcomes of axicabtagene ciloleucel in large B-cell lymphoma. <i>Blood Advances</i> , 2020, 4, 4898-4911.	2.5	238
63	Utility of repeating bone marrow biopsy for confirmation of complete response in multiple myeloma. <i>Blood Cancer Journal</i> , 2020, 10, 95.	2.8	3
64	Predictors of short-term survival in WaldenstrÃ¶m Macroglobulinemia. <i>Leukemia and Lymphoma</i> , 2020, 61, 2975-2979.	0.6	2
65	The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of multiple myeloma. , 2020, 8, e000734.		27
66	Clinical characteristics and treatment outcomes of newly diagnosed multiple myeloma with chromosome 1q abnormalities. <i>Blood Advances</i> , 2020, 4, 3509-3519.	2.5	58
67	Cytogenetic abnormalities in multiple myeloma: association with disease characteristics and treatment response. <i>Blood Cancer Journal</i> , 2020, 10, 82.	2.8	59
68	Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium. <i>Journal of Clinical Oncology</i> , 2020, 38, 3119-3128.	0.8	481
69	Utilizing multiparametric flow cytometry in the diagnosis of patients with primary plasma cell leukemia. <i>American Journal of Hematology</i> , 2020, 95, 637-642.	2.0	12
70	Long-term outcomes of IMiD-based trials in patients with immunoglobulin light-chain amyloidosis: a pooled analysis. <i>Blood Cancer Journal</i> , 2020, 10, 4.	2.8	18
71	HLA class-I and class-II restricted neoantigen loads predict overall survival in breast cancer. <i>Oncolmmunology</i> , 2020, 9, 1744947.	2.1	26
72	The chimeric antigen receptor-intensive care unit (CAR-ICU) initiative: Surveying intensive care unit practices in the management of CAR T-cell associated toxicities. <i>Journal of Critical Care</i> , 2020, 58, 58-64.	1.0	31

#	ARTICLE	IF	CITATIONS
73	Long-Term Survival and Gradual Recovery of B Cells in Patients with Refractory Large B Cell Lymphoma Treated with Axicabtagene Ciloleucel (Axi-Cel). <i>Blood</i> , 2020, 136, 40-42.	0.6	8
74	CARTITUDE-1: Phase 1b/2 Study of Ciltacabtagene Autoleucel, a B-Cell Maturation Antigen-Directed Chimeric Antigen Receptor T Cell Therapy, in Relapsed/Refractory Multiple Myeloma. <i>Blood</i> , 2020, 136, 22-25.	0.6	63
75	Cytokine Release Syndrome in Patients with Relapsed/Refractory Multiple Myeloma Treated with Ciltacabtagene Autoleucel in the Phase 1b/2 CARTITUDE-1 Study. <i>Blood</i> , 2020, 136, 45-46.	0.6	9
76	Health-Related Quality of Life in the Cartitude-1 Study of Ciltacabtagene Autoleucel for Relapsed/Refractory Multiple Myeloma. <i>Blood</i> , 2020, 136, 41-42.	0.6	8
77	MASS-FIX for the Diagnosis of Plasma Cell Disorders: A Single Institution Experience of 4118 Patients. <i>Blood</i> , 2020, 136, 48-49.	0.6	2
78	Continued Improvement in Survival of Patients with Newly Diagnosed Multiple Myeloma (MM). <i>Blood</i> , 2020, 136, 30-31.	0.6	4
79	Updated Results from the Phase I CRB-402 Study of Anti-Bcma CAR-T Cell Therapy bb21217 in Patients with Relapsed and Refractory Multiple Myeloma: Correlation of Expansion and Duration of Response with T Cell Phenotypes. <i>Blood</i> , 2020, 136, 25-26.	0.6	63
80	Phase I Trial of Systemic Administration of Vesicular Stomatitis Virus Genetically Engineered to Express NIS and Human Interferon Beta, in Patients with Relapsed or Refractory Multiple Myeloma (MM), Acute Myeloid Leukemia (AML), and T-Cell Neoplasms (TCL). <i>Blood</i> , 2020, 136, 7-8.	0.6	1
81	Sequential Comparison of Conventional Serum Immunofixation (IFE) to Mass Spectrometry-Based Assessment (MASS FIX) in Patients with Multiple Myeloma (MM). <i>Blood</i> , 2020, 136, 12-13.	0.6	3
82	Lines of Therapy before Autologous Stem Cell Transplant (ASCT) and CAR-T Infusion Affect Outcomes in Aggressive Non-Hodgkin's Lymphoma (NHL). <i>Blood</i> , 2020, 136, 29-30.	0.6	3
83	Comparison of Conventional Xrays with CT Based Approaches for Detection of Lytic Lesions in Multiple Myeloma. <i>Blood</i> , 2020, 136, 27-28.	0.6	0
84	The Prognostic Significance of Acquired 1q22 Gain in Multiple Myeloma. <i>Blood</i> , 2020, 136, 9-10.	0.6	0
85	Response to Bridging Therapy (BT) before CAR-T Cell Infusion Predicts Outcomes for Relapsed/Refractory (R/R) Aggressive B-Cell Non-Hodgkin Lymphoma (NHL). <i>Blood</i> , 2020, 136, 30-30.	0.6	1
86	The Utility of Granulocyte Colony Stimulating Factor in Patients Receiving Chimeric Antigen Receptor T-Cell Therapy with Axicabtagene Ciloleucel. <i>Blood</i> , 2020, 136, 23-25.	0.6	0
87	A Cross Sectional Evaluation of Light Chain N-Glycosylation By MASS-FIX in Plasma Cell Disorders. <i>Blood</i> , 2020, 136, 44-45.	0.6	0
88	Prognostic Impact of PET Findings Post-Transplant in Multiple Myeloma. <i>Blood</i> , 2020, 136, 15-16.	0.6	0
89	Prognostic Restaging after Treatment Initiation in Patients with AL Amyloidosis. <i>Blood</i> , 2020, 136, 6-7.	0.6	0
90	A 3-Question Symptom Assessment Score Can Predict Outcomes in Newly Diagnosed Multiple Myeloma (MM). <i>Blood</i> , 2020, 136, 21-22.	0.6	0

#	ARTICLE	IF	CITATIONS
91	Unmet Needs in AL Amyloidosis: Outcomes in the Modern Era Among the Highest Risk, Newly Diagnosed AL Amyloidosis Patients. <i>Blood</i> , 2020, 136, 31-32.	0.6	1
92	Utilization of hematopoietic stem cell transplantation for the treatment of multiple myeloma: a Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus statement. <i>Bone Marrow Transplantation</i> , 2019, 54, 353-367.	1.3	81
93	Ten-year survivors in AL amyloidosis: characteristics and treatment pattern. <i>British Journal of Haematology</i> , 2019, 187, 588-594.	1.2	40
94	Depth of organ response in AL amyloidosis is associated with improved survival: new proposed organ response criteria. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2019, 26, 101-102.	1.4	9
95	Use of Chimeric Antigen Receptor T Cell Therapy in Clinical Practice for Relapsed/Refractory Aggressive B Cell Non-Hodgkin Lymphoma: An Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 2305-2321.	2.0	132
96	Comparative analysis of staging systems in AL amyloidosis. <i>Leukemia</i> , 2019, 33, 811-814.	3.3	22
97	Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma. <i>New England Journal of Medicine</i> , 2019, 380, 1726-1737.	13.9	1,130
98	Natural history of multiple myeloma with de novo del(17p). <i>Blood Cancer Journal</i> , 2019, 9, 32.	2.8	38
99	Prognostic value of minimal residual disease and polyclonal plasma cells in myeloma patients achieving a complete response to therapy. <i>American Journal of Hematology</i> , 2019, 94, 751-756.	2.0	15
100	A Modern Primer on Light Chain Amyloidosis in 592 Patients With Mass Spectrometry-Verified Typing. <i>Mayo Clinic Proceedings</i> , 2019, 94, 472-483.	1.4	59
101	Impact of acquired del(17p) in multiple myeloma. <i>Blood Advances</i> , 2019, 3, 1930-1938.	2.5	41
102	Axicabtagene Ciloleucel Chimeric Antigen Receptor T Cell Therapy in Lymphoma With Secondary Central Nervous System Involvement. <i>Mayo Clinic Proceedings</i> , 2019, 94, 2361-2364.	1.4	12
103	Preventive Effects of Epinephrine for Critically Ill Patients? More Questions Waiting to Be Answered. <i>Digestive Diseases and Sciences</i> , 2019, 64, 283-284.	1.1	0
104	Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial. <i>Lancet Oncology</i> , The, 2019, 20, 31-42.	5.1	1,467
105	Optimizing deep response assessment for AL amyloidosis using involved free light chain level at end of therapy: failure of the serum free light chain ratio. <i>Leukemia</i> , 2019, 33, 527-531.	3.3	36
106	Patient Experience of Chimeric Antigen Receptor (CAR)-T Cell Therapy Vs. Stem Cell Transplant: Longitudinal Patient Reported Adverse Events, Cognition and Quality of Life. <i>Blood</i> , 2019, 134, 794-794.	0.6	14
107	Mortality of Patients with Multiple Myeloma after the Introduction of Novel Therapies in the United States. <i>Blood</i> , 2019, 134, 72-72.	0.6	2
108	A Comparison of Two-Year Outcomes in ZUMA-1 (Axicabtagene Ciloleucel) and SCHOLAR-1 in Patients with Refractory Large B Cell Lymphoma. <i>Blood</i> , 2019, 134, 4095-4095.	0.6	8

#	ARTICLE	IF	CITATIONS
109	Updated Results from an Ongoing Phase 1 Clinical Study of bb21217 Anti-Bcma CAR T Cell Therapy. <i>Blood</i> , 2019, 134, 927-927.	0.6	52
110	Utilizing Multiparametric Flow Cytometry to Identify Patients with Primary Plasma Cell Leukemia at Diagnosis. <i>Blood</i> , 2019, 134, 4334-4334.	0.6	1
111	Peak Lymphocyte Count after CAR T Infusion Is a Clinically Accessible Test That Correlates with Clinical Response in Axicabtagene Ciloleucel Therapy for Lymphoma. <i>Blood</i> , 2019, 134, 4106-4106.	0.6	6
112	Experience with Axicabtagene Ciloleucel (Axi-cel) in Patients with Secondary CNS Involvement: Results from the US Lymphoma CAR T Consortium. <i>Blood</i> , 2019, 134, 763-763.	0.6	42
113	Characteristics and Outcomes of Patients Receiving Bridging Therapy While Awaiting Manufacture of Standard of Care Axicabtagene Ciloleucel CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory Large B-Cell Lymphoma: Results from the US Lymphoma CAR-T Consortium. <i>Blood</i> , 2019, 134, 245-245.	0.6	37
114	Prognostic Implications of Serum Monoclonal Protein Positivity By Mass-Fix in Bone Marrow Minimal Residual Disease Negative (MRD-) Patients with Multiple Myeloma. <i>Blood</i> , 2019, 134, 4386-4386.	0.6	2
115	Baseline Hypoalbuminemia Does Not Appear to be an Adverse Prognostic Factor in Patients with Relapse/Refractory B-Cell Lymphomas Treated with Axicabtagene Ciloleucel (axi-cel). <i>Blood</i> , 2019, 134, 5343-5343.	0.6	1
116	Waldenström Macroglobulinemia with Excess Plasma Cells: Is It a Distinct Entity?. <i>Blood</i> , 2019, 134, 1532-1532.	0.6	0
117	Characteristics of Patients with Relapsed/Refractory Burkitt Non-Hodgkin Lymphoma (NHL): Impact on the Feasibility of CAR-T Cell Therapy. <i>Blood</i> , 2019, 134, 5352-5352.	0.6	0
118	Determinants of Clinical Trial Participation and Impact on Survival Outcomes Among Patients with Newly Diagnosed Multiple Myeloma. <i>Blood</i> , 2019, 134, 5833-5833.	0.6	0
119	A Novel Approach to Risk Stratification in Multiple Myeloma Using ISS Stage and FISH. <i>Blood</i> , 2019, 134, 1800-1800.	0.6	1
120	Clinical Outcomes and Cytogenetic Features of Primary Plasma Cell Leukemia (pPCL) in the Era of Novel Agent Induction Therapy. <i>Blood</i> , 2019, 134, 5490-5490.	0.6	1
121	Central Nervous System Involvement in Peripheral T-Cell Lymphoma. <i>Blood</i> , 2019, 134, 5293-5293.	0.6	2
122	Prognostic significance of circulating plasma cells by multi-parametric flow cytometry in light chain amyloidosis. <i>Leukemia</i> , 2018, 32, 1421-1426.	3.3	8
123	Depth of organ response in AL amyloidosis is associated with improved survival: grading the organ response criteria. <i>Leukemia</i> , 2018, 32, 2240-2249.	3.3	64
124	Bendamustine and rituximab (BR) versus dexamethasone, rituximab, and cyclophosphamide (DRC) in patients with Waldenström macroglobulinemia. <i>Annals of Hematology</i> , 2018, 97, 1417-1425.	0.8	71
125	Prognostic significance of interphase FISH in monoclonal gammopathy of undetermined significance. <i>Leukemia</i> , 2018, 32, 1811-1815.	3.3	28
126	Toxicity management after chimeric antigen receptor T cell therapy: one size does not fit 'ALL'. <i>Nature Reviews Clinical Oncology</i> , 2018, 15, 218-218.	12.5	114

#	ARTICLE	IF	CITATIONS
127	Efficacy of VDT PACE-like regimens in treatment of relapsed/refractory multiple myeloma. American Journal of Hematology, 2018, 93, 179-186.	2.0	49
128	<i>MYD88</i> mutation status does not impact overall survival in Waldenström macroglobulinemia. American Journal of Hematology, 2018, 93, 187-194.	2.0	57
129	Chimeric antigen receptor T-cell therapy " assessment and management of toxicities. Nature Reviews Clinical Oncology, 2018, 15, 47-62.	12.5	1,659
130	Revised diagnostic criteria for plasma cell leukemia: results of a Mayo Clinic study with comparison of outcomes to multiple myeloma. Blood Cancer Journal, 2018, 8, 116.	2.8	64
131	Overall survival of transplant eligible patients with newly diagnosed multiple myeloma: comparative effectiveness analysis of modern induction regimens on outcome. Blood Cancer Journal, 2018, 8, 125.	2.8	29
132	Phase 1/2 trial of ixazomib, cyclophosphamide and dexamethasone in patients with previously untreated symptomatic multiple myeloma. Blood Cancer Journal, 2018, 8, 70.	2.8	18
133	Serum free light chain measurements to reduce 24h urine monitoring in patients with multiple myeloma with measurable urine monoclonal protein. American Journal of Hematology, 2018, 93, 1207-1210.	2.0	3
134	Independent Prognostic Value of Stroke Volume Index in Patients With Immunoglobulin Light Chain Amyloidosis. Circulation: Cardiovascular Imaging, 2018, 11, e006588.	1.3	51
135	Predictors of symptomatic hyperviscosity in Waldenström macroglobulinemia. American Journal of Hematology, 2018, 93, 1384-1393.	2.0	24
136	Posttransplant autoimmune encephalitis. Neurology: Neuroimmunology and NeuroInflammation, 2018, 5, e497.	3.1	24
137	Risk stratification of smoldering multiple myeloma incorporating revised IMWG diagnostic criteria. Blood Cancer Journal, 2018, 8, 59.	2.8	171
138	2-Year Follow-up and High-Risk Subset Analysis of Zuma-1, the Pivotal Study of Axicabtagene Ciloleucel (Axi-Cel) in Patients with Refractory Large B Cell Lymphoma. Blood, 2018, 132, 2967-2967.	0.6	13
139	Axicabtagene Ciloleucel (Axi-cel) CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory Large B-Cell Lymphoma: Real World Experience. Blood, 2018, 132, 91-91.	0.6	81
140	Durability of response in ZUMA-1, the pivotal phase 2 study of axicabtagene ciloleucel (Axi-Cel) in patients (Pts) with refractory large B-cell lymphoma.. Journal of Clinical Oncology, 2018, 36, 3003-3003.	0.8	17
141	Systemic misfolding of immunoglobulins in the test tube and in the cell. FASEB Journal, 2018, 32, 247.3.	0.2	2
142	Comparative Analysis of Staging Systems in AL Amyloidosis. Blood, 2018, 132, 3228-3228.	0.6	0
143	Treatment Facility Volume and Outcomes in Waldenstrom Macroglobulinemia. Blood, 2018, 132, 622-622.	0.6	1
144	Depth of Response in Waldenstrom Macroglobulinemia. Blood, 2018, 132, 4141-4141.	0.6	2

#	ARTICLE	IF	CITATIONS
145	Impact of Acquired Del(17p) in Patients with Multiple Myeloma. <i>Blood</i> , 2018, 132, 4449-4449.	0.6	0
146	Long-Term AL Amyloidosis Survivors Among Non-Selected Referral Population. <i>Blood</i> , 2018, 132, 3226-3226.	0.6	0
147	Optimizing Deep Response Assessment for AL Amyloidosis Using Involved Free Light Chain Level at End of Therapy. <i>Blood</i> , 2018, 132, 3227-3227.	0.6	0
148	Impact of MYD88L265P mutation Status on Histological Transformation of Waldenstrom Macroglobulinemia. <i>Blood</i> , 2018, 132, 2884-2884.	0.6	1
149	Characterization of Exceptional Responders to Autologous Stem Cell Transplantation in Multiple Myeloma. <i>Blood</i> , 2018, 132, 4615-4615.	0.6	0
150	Patient-Reported Outcome Driven Case Management System for Hematology – a Prospective Study. <i>Blood</i> , 2018, 132, 719-719.	0.6	1
151	Overuse of organ biopsies in immunoglobulin light chain amyloidosis (AL): the consequence of failure of early recognition. <i>Annals of Medicine</i> , 2017, 49, 545-551.	1.5	45
152	Hematology patient reported symptom screen to assess quality of life for AL amyloidosis. <i>American Journal of Hematology</i> , 2017, 92, 435-440.	2.0	16
153	The prognostic value of multiparametric flow cytometry in AL amyloidosis at diagnosis and at the end of first-line treatment. <i>Blood</i> , 2017, 129, 82-87.	0.6	50
154	Improved outcomes for newly diagnosed AL amyloidosis between 2000 and 2014: cracking the glass ceiling of early death. <i>Blood</i> , 2017, 129, 2111-2119.	0.6	249
155	Immunoparesis in newly diagnosed AL amyloidosis is a marker for response and survival. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2017, 24, 40-41.	1.4	4
156	Immunoparesis status in AL amyloidosis at diagnosis affects response and survival by regimen type. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2017, 24, 44-45.	1.4	1
157	Prevalence and predictors of thyroid functional abnormalities in newly diagnosed AL amyloidosis. <i>Journal of Internal Medicine</i> , 2017, 281, 611-619.	2.7	15
158	The prognostic significance of polyclonal bone marrow plasma cells in patients with relapsing multiple myeloma. <i>American Journal of Hematology</i> , 2017, 92, E507-E512.	2.0	5
159	Therapy for Relapsed Multiple Myeloma. <i>Mayo Clinic Proceedings</i> , 2017, 92, 578-598.	1.4	115
160	Diagnosis and Management of Waldenström Macroglobulinemia. <i>JAMA Oncology</i> , 2017, 3, 1257.	3.4	110
161	Mesenchymal stromal cells protect human cardiomyocytes from amyloid fibril damage. <i>Cytotherapy</i> , 2017, 19, 1426-1437.	0.3	9
162	Elevation of serum lactate dehydrogenase in <sc>AL</sc> amyloidosis reflects tissue damage and is an adverse prognostic marker in patients not eligible for stem cell transplantation. <i>British Journal of Haematology</i> , 2017, 178, 888-895.	1.2	15

#	ARTICLE	IF	CITATIONS
163	Dexamethasone, rituximab and cyclophosphamide for relapsed and/or refractory and treatment-naïve patients with Waldenstrom macroglobulinemia. <i>British Journal of Haematology</i> , 2017, 179, 98-105.	1.2	25
164	Efficacy of daratumumab-based therapies in patients with relapsed, refractory multiple myeloma treated outside of clinical trials. <i>American Journal of Hematology</i> , 2017, 92, 1146-1155.	2.0	25
165	Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma. <i>New England Journal of Medicine</i> , 2017, 377, 2531-2544.	13.9	3,865
166	Pomalidomide, bortezomib, and dexamethasone for patients with relapsed lenalidomide-refractory multiple myeloma. <i>Blood</i> , 2017, 130, 1198-1204.	0.6	54
167	Clinical heterogeneity of diffuse large B cell lymphoma following failure of frontline immunochemotherapy. <i>British Journal of Haematology</i> , 2017, 179, 50-60.	1.2	49
168	Immunosuppressive CD14 <sup>+</sup> HLA-DR <sup>lo/neg</sup> monocytes are elevated in pancreatic cancer and are primed by tumor-derived exosomes. <i>Oncot Immunology</i> , 2017, 6, e1252013.	2.1	59
169	Beta-blockers improve survival outcomes in patients with multiple myeloma: a retrospective evaluation. <i>American Journal of Hematology</i> , 2017, 92, 50-55.	2.0	41
170	Presentation and Outcomes of Localized Immunoglobulin Light Chain Amyloidosis. <i>Mayo Clinic Proceedings</i> , 2017, 92, 908-917.	1.4	72
171	Durable Clinical Responses in Heavily Pretreated Patients with Relapsed/Refractory Multiple Myeloma: Updated Results from a Multicenter Study of bb2121 Anti-Bcma CAR T Cell Therapy. <i>Blood</i> , 2017, 130, 740-740.	0.6	67
172	Clinical and biologic covariates of outcomes in ZUMA-1: A pivotal trial of axicabtagene ciloleucel (axi-cel; KTE-C19) in patients with refractory aggressive non-Hodgkin lymphoma (r-NHL). <i>Journal of Clinical Oncology</i> , 2017, 35, 7512-7512.	0.8	22
173	Induction therapy preautologous stem cell transplantation in immunoglobulin light chain amyloidosis: a retrospective evaluation. <i>American Journal of Hematology</i> , 2016, 91, 984-988.	2.0	45
174	Immunoparesis status in immunoglobulin light chain amyloidosis at diagnosis affects response and survival by regimen type. <i>Haematologica</i> , 2016, 101, 1102-1109.	1.7	9
175	Myelomatous Involvement of the Central Nervous System. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2016, 16, 644-654.	0.2	38
176	Systemic Immunoglobulin Light Chain Amyloidosis—Associated Myopathy: Presentation, Diagnostic Pitfalls, and Outcome. <i>Mayo Clinic Proceedings</i> , 2016, 91, 1354-1361.	1.4	43
177	Outcomes of patients with renal monoclonal immunoglobulin deposition disease. <i>American Journal of Hematology</i> , 2016, 91, 1123-1128.	2.0	76
178	Long-term outcome of patients with POEMS syndrome: An update of the Mayo Clinic experience. <i>American Journal of Hematology</i> , 2016, 91, 585-589.	2.0	57
179	N-terminal fragment of the type B natriuretic peptide (NT-proBNP) contributes to a simple new frailty score in patients with newly diagnosed multiple myeloma. <i>American Journal of Hematology</i> , 2016, 91, 1129-1134.	2.0	71
180	Cell Damage in Light Chain Amyloidosis. <i>Journal of Biological Chemistry</i> , 2016, 291, 19813-19825.	1.6	58

#	ARTICLE	IF	CITATIONS
181	IAP antagonists induce anti-tumor immunity in multiple myeloma. <i>Nature Medicine</i> , 2016, 22, 1411-1420.	15.2	133
182	Clinical characteristics and outcomes in biclonal gammopathies. <i>American Journal of Hematology</i> , 2016, 91, 473-475.	2.0	30
183	Safety and Accuracy of Percutaneous Image-Guided Core Biopsy of the Spleen. <i>American Journal of Roentgenology</i> , 2016, 206, 655-659.	1.0	54
184	The impact of dialysis on the survival of patients with immunoglobulin light chain (AL) amyloidosis undergoing autologous stem cell transplantation. <i>Nephrology Dialysis Transplantation</i> , 2016, 31, 1284-1289.	0.4	25
185	Bendamustine and Rituximab Versus Dexamethasone, Rituximab and Cyclophosphamide in Patients with Waldenstrom Macroglobulinemia (WM). <i>Blood</i> , 2016, 128, 2968-2968.	0.6	4
186	PD-1 Blockade with Pembrolizumab in Relapsed CLL Including Richter's Transformation: An Updated Report from a Phase 2 Trial (MC1485). <i>Blood</i> , 2016, 128, 4392-4392.	0.6	8
187	Thyroid Functional Abnormalities in Newly Diagnosed AL Amyloidosis: Frequency and Influence By Type of Organ Involvement and Disease Burden. <i>Blood</i> , 2016, 128, 3273-3273.	0.6	0
188	Changes in Uninvolved Immunoglobulins during Multiple Myeloma Therapy. <i>Blood</i> , 2016, 128, 3251-3251.	0.6	0
189	Beta-Blockers Improved Survival Outcomes in Patients with Multiple Myeloma: A Retrospective Evaluation. <i>Blood</i> , 2016, 128, 3306-3306.	0.6	0
190	The Prognostic Significance of Polyclonal Bone Marrow Plasma Cells in Patients with Actively Relapsing Multiple Myeloma. <i>Blood</i> , 2016, 128, 1194-1194.	0.6	0
191	Fluorescence in-Situ Hybridization (FISH) Analysis in Untreated AL Amyloidosis Has an Independent Prognostic Impact By Abnormality Type and Treatment Category. <i>Blood</i> , 2016, 128, 3269-3269.	0.6	0
192	Outcome of Very Young (â‰¥ 40 years) Patients with Immunoglobulin Light Chain Amyloidosis (AL): A Case Control Study. <i>Blood</i> , 2016, 128, 5576-5576.	0.6	0
193	Novel Mutations in NOTCH and Altered Wnt/ $\beta$ 2-Catenin Pathway Indicate a Role of Embryonic Signals in the Pathogenesis of T-Cell Prolymphocytic Leukemia. <i>Blood</i> , 2016, 128, 4103-4103.	0.6	1
194	Predictors of early response to initial therapy in patients with newly diagnosed symptomatic multiple myeloma. <i>American Journal of Hematology</i> , 2015, 90, 888-891.	2.0	18
195	A Method for Identification and Analysis of Non-Overlapping Myeloid Immunophenotypes in Humans. <i>PLoS ONE</i> , 2015, 10, e0121546.	1.1	100
196	Danhong Promotes Angiogenesis in Diabetic Mice after Critical Limb Ischemia by Activation of CSE-H <sub>2</sub> S-VEGF Axis. <i>Evidence-based Complementary and Alternative Medicine</i> , 2015, 2015, 1-8.	0.5	9
197	Intratumoral CD14+ Cells and Circulating CD14+HLA-DRlo/neg Monocytes Correlate with Decreased Survival in Patients with Clear Cell Renal Cell Carcinoma. <i>Clinical Cancer Research</i> , 2015, 21, 4224-4233.	3.2	33
198	Kinetics of organ response and survival following normalization of the serum free light chain ratio in AL amyloidosis. <i>American Journal of Hematology</i> , 2015, 90, 181-186.	2.0	76

#	ARTICLE	IF	CITATIONS
199	Immune independent crosstalk between lymphoma and myeloid suppressor CD14 <sup>+</sup> HLA-DR <sup>low/neg</sup> monocytes mediates chemotherapy resistance. <i>OncImmunology</i> , 2015, 4, e996470.	2.1	10
200	In Patients with Light-Chain (AL) Amyloidosis Myocardial Contraction Fraction (MCF) Is a Simple, but Powerful Prognostic Measure That Can be Calculated from a Standard Echocardiogram (ECHO). <i>Blood</i> , 2015, 126, 1774-1774.	0.6	6
201	Randomized Phase 2 Trial of Two Different Doses of Ixazomib in Patients with Relapsed Multiple Myeloma Not Refractory to Bortezomib. <i>Blood</i> , 2015, 126, 3050-3050.	0.6	8
202	Incidence and Outcomes of Treatment Refractory Diffuse Large B-Cell Lymphoma in the Immunochemotherapy Era. <i>Blood</i> , 2015, 126, 3992-3992.	0.6	1
203	Presentation and Outcomes of Localized Amyloidosis: The Mayo Clinic Experience. <i>Blood</i> , 2015, 126, 4197-4197.	0.6	5
204	PD-1 Blockade with Pembrolizumab (MK-3475) in Relapsed/Refractory CLL Including Richter Transformation: An Early Efficacy Report from a Phase 2 Trial (MC1485). <i>Blood</i> , 2015, 126, 834-834.	0.6	17
205	N-Terminal Fragment of the Type-B Natriuretic Peptide (NT-proBNP) Is a Prognostic Factor for Overall Survival in Newly Diagnosed Patients with Multiple Myeloma (MM). <i>Blood</i> , 2015, 126, 3292-3292.	0.6	0
206	Anti-Tumor Phagocytic Cell Activation in Multiple Myeloma By the IAP Antagonist LCL161: Results of a Phase II Clinical Trial. <i>Blood</i> , 2015, 126, 3039-3039.	0.6	0
207	AL Amyloidosis and Patient Reported Quality of Life. <i>Blood</i> , 2015, 126, 3317-3317.	0.6	0
208	Immunoglobulin light chain amyloidosis is diagnosed late in patients with preexisting plasma cell dyscrasias. <i>American Journal of Hematology</i> , 2014, 89, 1051-1054.	2.0	32
209	Strategies for improving the reporting of human immunophenotypes by flow cytometry. , 2014, 2, 18.		11
210	Cancer Vaccines in the World of Immune Suppressive Monocytes (CD14+HLA-DR <sup>lo/neg</sup> Cells): The Gateway to Improved Responses. <i>Frontiers in Immunology</i> , 2014, 5, 147.	2.2	55
211	Trends in survival of patients with primary plasma cell leukemia: A population-based analysis from 1973 to 2010.. <i>Journal of Clinical Oncology</i> , 2014, 32, 8608-8608.	0.8	1
212	Presence and function of CD14+CD16-HLADR <sup>low</sup> monocytes in the peripheral blood of patients with T-cell non-Hodgkin lymphoma (NHL).. <i>Journal of Clinical Oncology</i> , 2014, 32, e19539-e19539.	0.8	0
213	Immune monitoring using the predictive power of immune profiles. , 2013, 1, 7.		50
214	Management of Newly Diagnosed Symptomatic Multiple Myeloma: Updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Guidelines 2013. <i>Mayo Clinic Proceedings</i> , 2013, 88, 360-376.	1.4	440
215	Coexistent Multiple Myeloma or Increased Bone Marrow Plasma Cells Define Equally High-Risk Populations in Patients With Immunoglobulin Light Chain Amyloidosis. <i>Journal of Clinical Oncology</i> , 2013, 31, 4319-4324.	0.8	193
216	Soluble ST2 (sST2) Is a Novel Valuable Prognostic Marker Among Patients With Immunoglobulin Light Chain (AL) Amyloidosis. <i>Blood</i> , 2013, 122, 3095-3095.	0.6	1

#	ARTICLE	IF	CITATIONS
217	Therapy Related MDS/AML In Multiple Myeloma Patients In The Era Of Novel Agents. Blood, 2013, 122, 3117-3117.	0.6	2
218	Implications of rapidity of response to initial therapy in multiple myeloma.. Journal of Clinical Oncology, 2013, 31, 8606-8606.	0.8	0
219	Definition of a high-risk population among patients with AL amyloidosis not undergoing autologous stem cell transplantation using bone marrow plasmacytosis and the presence of CRAB.. Journal of Clinical Oncology, 2013, 31, 8516-8516.	0.8	0
220	Continued monoclonal protein response beyond day 100 after auto-transplantation for multiple myeloma.. Journal of Clinical Oncology, 2013, 31, 8587-8587.	0.8	0
221	Autologous Stem Cell Transplantation In Immunoglobulin Light Chain Amyloidosis With Factor X Deficien. Blood, 2013, 122, 2151-2151.	0.6	9
222	Effect Of Immediate Prior-Line Lenalidomide Or Thalidomide Therapy On Response To Pomalidomide In Multiple Myeloma. Blood, 2013, 122, 1979-1979.	0.6	0
223	Long Term Response To Lenalidomide With and Without Continuous Therapy Among Patients With Newly Diagnosed Multiple Myeloma. Blood, 2013, 122, 3209-3209.	0.6	0
224	Tumor Monocyte Cross Talk Promotes Chemotherapy Resistance In Lymphoma. Blood, 2013, 122, 1774-1774.	0.6	0
225	Association of an increased frequency of CD14 <sup>+</sup> HLA-DR <sup>lo/neg</sup> monocytes with decreased time to progression in chronic lymphocytic leukaemia (CLL). British Journal of Haematology, 2012, 156, 674-676.	1.2	58
226	Continued Improvement in Survival in Multiple Myeloma and the Impact of Novel Agents. Blood, 2012, 120, 3972-3972.	0.6	7
227	Survival After Second, Third, and Fourth Line Therapy Better Than Expected in Patients with Previously Treated AL Amyloidosis Who Were Not Transplant Candidates At Diagnosis.. Blood, 2012, 120, 946-946.	0.6	1
228	Outcomes of Patients with POEMS Syndrome Treated Initially with Radiation. Blood, 2012, 120, 448-448.	0.6	0
229	Importance of Achieving Sustained Stringent Complete Response (sCR) Following Autologous Stem Cell Transplantation in Multiple Myeloma. Blood, 2012, 120, 1988-1988.	0.6	0
230	Immunosuppressive CD14 <sup>+</sup> HLA-DR <sup>low</sup> monocytes in B-cell non-Hodgkin lymphoma. Blood, 2011, 117, 872-881.	0.6	218
231	Clinical Application of Mesenchymal Stem Cells in the Treatment and Prevention of Graft-versus-Host Disease. Advances in Hematology, 2011, 2011, 1-17.	0.6	59
232	Immunosuppressive CD14 <sup>+</sup> HLA-DR <sup>low</sup> monocytes in prostate cancer. Prostate, 2010, 70, 443-455.	1.2	233
233	Systemic immune suppression in glioblastoma: the interplay between CD14 <sup>+</sup> HLA-DR <sup>lo/neg</sup> monocytes, tumor factors, and dexamethasone. Neuro-Oncology, 2010, 12, 631-644.	0.6	194